H. Hammers

16 ABBV-CLS-484: A Novel Oral PTPN2/1 Inhibitor for Cancer Immunotherapy

Abstract Background ABBV-CLS-484 is a first-in-class oral PTPN2/N1 inhibitor with a dual mechanism of action that both increases the immunogenicity of tumor cells and augments the antitumor T cell response. It has monotherapy efficacy in multiple preclinical tumor models, with comparable activity to anti-PD-1 in many c...